Jolanda H. Schieving

Jolanda H. Schieving

Auto-generated profile, based on publicly available information

Jolanda H. Schieving

Department of Pediatric Neurology, Radboud University Medical Centre, Amalia Children's Hospital, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
LVLisenka E.L.M. Vissers
Lisenka E.L.M. Vissers
KNKirsten J.M. van Nimwegen
Kirsten J.M. van Nimwegen
JSJolanda H. Schieving
Jolanda H. Schieving
EKErik-Jan Kamsteeg
Erik-Jan Kamsteeg
TKTjitske Kleefstra
Tjitske Kleefstra
MWMichèl A.A.P. Willemsen
Michèl A.A.P. Willemsen
Implementation of novel genetic diagnostic tests is generally driven by technological advances because they promise shorter turnaround times and/or higher diagnostic yields. Other aspects, including impact on clinical management or cost-effectiveness, are often not assessed in detail prior to implementation. We studied the clinical utility of whole-exome sequencing (WES) in complex pediatric neurology in terms of diagnostic yield and costs. We analyzed 150 patients (and their parents) presenting with complex neurological disorders of suspected genetic origin. In a parallel study, all patients received both the standard diagnostic workup (e.g., cerebral imaging, muscle biopsies or lumbar punctures, and sequential gene-by-gene–based testing) and WES simultaneously. Our unique study design allowed direct comparison of diagnostic yield of both trajectories and provided insight into the economic implications of implementing WES in this diagnostic trajectory. We showed that WES identified significantly more conclusive diagnoses (29.3%) than the standard care pathway (7.3%) without incurring higher costs. Exploratory analysis of WES as a first-tier diagnostic test indicates that WES may even be cost-saving, depending on the extent of other tests being omitted. Our data support such a use of WES in pediatric neurology for disorders of presumed genetic origin. Genet Med advance online publication 23 March 2017

15 May 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CGCharlotte Gehin
Charlotte Gehin
MLMuseer Lone
Museer Lone
WLWinston Lee
Winston Lee
LCLaura Capolupo
Laura Capolupo
SHSylvia Ho
Sylvia Ho
VGVincenzo A. Gennarino
Vincenzo A. Gennarino
Neural differentiation, synaptic transmission, and action potential propagation depend on membrane sphingolipids, whose metabolism is tightly regulated. Mutations in the ceramide transporter CERT (CERT1), which is involved in sphingolipid biosynthesis, are associated with intellectual disability, but the pathogenic mechanism remains obscure. Here, we characterize 31 individuals with de novo missense variants in CERT1. Several variants fall into a previously uncharacterized dimeric helical domain that enables CERT homeostatic inactivation, without which sphingolipid production goes unchecked. The clinical severity reflects the degree to which CERT autoregulation is disrupted, and inhibiting CERT pharmacologically corrects morphological and motor abnormalities in a Drosophila model of the disease, which we call ceramide transporter (CerTra) syndrome. These findings uncover a central role for CERT autoregulation in the control of sphingolipid biosynthetic flux, provide unexpected insight into the structural organization of CERT, and suggest a possible therapeutic approach for patients with CerTra syndrome.

1 March 2015 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
KNK.J.M. van Nimwegen
K.J.M. van Nimwegen
JSJ.H. Schieving
J.H. Schieving
MWMichèl Willemsen
Michèl Willemsen
JVJoris Andre Andre Veltman
Joris Andre Andre Veltman
Simone van der BurgSimone van der Burg
Simone van der Burg
JGJ.P.C. Grutters
J.P.C. Grutters

1 June 2016 in Pediatric Neurology
Verified
Journal Article
Closed access
RMRoderick Maas
Roderick Maas
JSJolanda H. Schieving
Jolanda H. Schieving
MSMeyke Schouten
Meyke Schouten
EKErik-Jan Kamsteeg
Erik-Jan Kamsteeg
BWBart P.C. van de Warrenburg
Bart P.C. van de Warrenburg

15 January 2022 in Genes
Verified
Journal Article
Open access
PDF file
DNDóra Nagy
Dóra Nagy
SVSarah Verheyen
Sarah Verheyen
KWKristen M. Wigby
Kristen M. Wigby
ABArtem Borovikov
Artem Borovikov
ASArtem A Sharkov
Artem A Sharkov
DWDenisa Weis
Denisa Weis
POGZ-related disorders (also known as White-Sutton syndrome) encompass a wide range of neurocognitive abnormalities and other accompanying anomalies. Disease severity varies widely among POGZ patients and studies investigating genotype-phenotype association are scarce. Therefore, our aim was to collect data on previously unreported POGZ patients and perform a large-scale phenotype-genotype comparison from published data. Overall, 117 POGZ patients’ genotype and phenotype data were included in the analysis, including 12 novel patients. A severity scoring system was developed for the comparison. Mild and severe phenotypes were compared with the types and location of the variants and the predicted presence or absence of nonsense-mediated RNA decay (NMD). Missense variants were more often associated with mild phenotypes (p = 0.0421) and truncating variants predicted to escape NMD presented with more severe phenotypes (p < 0.0001). Within this group, variants in the prolin-rich region of the POGZ protein were associated with the most severe phenotypes (p = 0.0004). Our study suggests that gain-of-function or dominant negative effect through escaping NMD and the location of the variants in the prolin-rich domain of the protein may play an important role in the severity of manifestations of POGZ–associated neurodevelopmental disorders.

24 November 2015 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MCMaurice C. Cox
Maurice C. Cox
JKJohannes M. Kusters
Johannes M. Kusters
CGCorrie E. Gidding
Corrie E. Gidding
JSJolanda H. Schieving
Jolanda H. Schieving
ELErik J. van Lindert
Erik J. van Lindert
GJGeert O. Janssens
Geert O. Janssens
To report on the acute toxicity in children with medulloblastoma undergoing intensity-modulated radiation therapy (IMRT) with daily intrafractionally modulated junctions. Newly diagnosed patients, aged 3–21, with standard-risk (SR) or high-risk (HR) medulloblastoma were eligible. A dose of 23.4 or 36.0Gy in daily fractions of 1.8Gy was prescribed to the craniospinal axis, followed by a boost to the primary tumor bed (54 or 55.8Gy) and metastases (39.6–55.8Gy), when indicated. Weekly, an intravenous bolus of vincristine was combined for patients with SR medulloblastoma and patients participating in the COG-ACNS-0332 study. Common toxicity criteria (CTC, version 2.0) focusing on skin, alopecia, voice changes, conjunctivitis, anorexia, dysphagia, gastro-intestinal symptoms, headache, fatigue and hematological changes were scored weekly during radiotherapy. From 2010 to 2014, data from 15 consecutive patients (SR, n = 7; HR, n = 8) were collected. Within 72 h from onset of treatment, vomiting (66 %) and headache (46 %) occurred. During week 3 of treatment, a peak incidence in constipation (33 %) and abdominal pain/cramping (40 %) was observed, but only in the subgroup of patients (n = 9) receiving vincristine (constipation: 56 vs 0 %, P = .04; pain/cramping: 67 vs 0 %, P = .03). At week 6, 73 % of the patients developed faint erythema of the cranial skin with dry desquamation (40 %) or moist desquamation confined to the skin folds of the auricle (33 %). No reaction of the skin overlying the spinal target volume was observed. Headache at onset and gastro-intestinal toxicity, especially in patients receiving weekly vincristine, were the major complaints of patients with medulloblastoma undergoing craniospinal irradiation with IMRT.